Laman UtamaAXGN • NASDAQ
AxoGen, Inc Common Stock
$18.07
13 Jan, 12:07:36 PTG GMT-5 · USD · NASDAQ · Penafian
SahamSekuriti tersenarai ASIbu pejabat di AS
Tutup sebelumnya
$18.05
Julat hari
$17.17 - $18.49
Julat tahun
$5.56 - $18.49
Permodalan pasaran
801.61J USD
Bilangan Purata
391.56K
Nisbah P/E
-
Hasil dividen
-
Pertukaran utama
NASDAQ
Kewangan
Penyata Pendapatan
Hasil
Pendapatan bersih
(USD)Sep 2024Perubahan T/T
Hasil
48.64J17.86%
Perbelanjaan pengendalian
36.75J2.87%
Pendapatan bersih
-1.86J54.56%
Margin untung bersih
-3.8261.45%
Pendapatan bagi setiap syer
0.07600.00%
EBITDA
1.40J150.05%
Kadar cukai berkesan
——
Jumlah aset
Jumlah liabiliti
(USD)Sep 2024Perubahan T/T
Pelaburan tunai dan jangka pendek
24.53J-24.73%
Jumlah aset
191.98J-1.36%
Jumlah liabiliti
92.58J-4.38%
Jumlah ekuiti
99.41J—
Syer tertunggak
44.01J—
Harga kepada buku
7.99—
Pulangan pada aset
-0.41%—
Pulangan pada modal
-0.47%—
Perubahan bersih dalam tunai
(USD)Sep 2024Perubahan T/T
Pendapatan bersih
-1.86J54.56%
Tunai daripada operasi
3.90J139.91%
Tunai daripada pelaburan
-5.00J-183.42%
Tunai daripada pembiayaan
572.00K11,340.00%
Perubahan bersih dalam tunai
-527.00K-106.91%
Aliran tunai bebas
3.60J424.35%
Perihal
Axogen is a developer of surgical solutions, including human tissue grafts, based in Alachua, Florida. Axogen products are designed to remedy peripheral nerve damage. In 2013 the company raised $18 million in its initial public offering. Axogen uses a cell graft technology AVANCE to mimic a human nerve. The company also creates nerve connectors and soft tissue membranes. The company reports sensory and movement recovery in 87 percent of patients with peripheral nerve injuries. Axogen is part of the Sid Martin Biotechnology Incubator. As of 2019, Axogen was the only commercially available allograft approved by the Food and Drug Administration for clinical use. Wikipedia
Diasaskan
2002
Tapak web
Pekerja
427
Cari
Kosongkan carian
Tutup carian
Apl Google
Menu utama